DexCom Inc. Common Stock (DXCM)
Stock · NASDAQ · Health Care
$90.8as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$62.3
Industry
Medical/Dental Instruments
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 11,000
- Website
- www.dexcom.com/
Fundamentals
- 1-day range
- $82.09$85.06
- Market cap
- $31.33B
- P/E (trailing)
- 34.53
- P/E (forward)
- 27.12
- EPS (trailing)
- $2.51
- Dividend yield
- —
- Beta
- 1.47
- Avg. volume
- 5.77M
52-week range
$54.11$92.59
Next earnings: October 29, 2026 · EPS estimate $0.67confirmed
How DexCom Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
25 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$115
+26.7%
Median
$93
+2.4%
Low
$79
-13.0%
DexCom Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DXCMDexCom Inc. Common Stock$90.8▲ 1.69%Market cap $31.33BP/E 34.53$54.11$92.59
- RMDResMed Inc. Common Stock$240.24▲ 1.90%Market cap $32.38BP/E 21.47$180.27$284.87
- MDLNMedline Inc. Class A Common Stock$35.29▲ 1.85%Market cap $45.34BP/E 67.50$32.49$50.88
- BAXBaxter International Inc. Common Stock$26.12▲ 0.77%Market cap $13.96BP/E —$15.73$30
- BDXBecton Dickinson and Company Common Stock$189.6▲ 0.78%Market cap $48.79BP/E 53.21$127.59$193.07
- GMEDGlobus Medical Inc. Class A Common Stock$83.06▲ 0.63%Market cap $11.01BP/E 21.55$54.15$101.4
- GKOSGlaukos Corporation Common Stock$179.56▼ 1.29%Market cap $10.09BP/E —$73.16$191.62
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DXCM DexCom Inc. Common Stock | $31.33B | 34.53 | $90.8 | ▲ 1.69% | $54.11$92.59 |
| RMD ResMed Inc. Common Stock | $32.38B | 21.47 | $240.24 | ▲ 1.90% | $180.27$284.87 |
| MDLN Medline Inc. Class A Common Stock | $45.34B | 67.50 | $35.29 | ▲ 1.85% | $32.49$50.88 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $26.12 | ▲ 0.77% | $15.73$30 |
| BDX Becton Dickinson and Company Common Stock | $48.79B | 53.21 | $189.6 | ▲ 0.78% | $127.59$193.07 |
| GMED Globus Medical Inc. Class A Common Stock | $11.01B | 21.55 | $83.06 | ▲ 0.63% | $54.15$101.4 |
| GKOS Glaukos Corporation Common Stock | $10.09B | — | $179.56 | ▼ 1.29% | $73.16$191.62 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair ValuationChartMill · 8/27/2026
- FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose TrackingBenzinga · 8/26/2026
- The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical ProductsSeekingAlpha · 8/24/2026
- 1 Healthcare Stock to Target This Week and 2 Facing HeadwindsYahoo · 8/20/2026
- Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical SetupChartMill · 8/20/2026
- Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?Yahoo · 8/19/2026
- DexCom (DXCM) Stock May Trade At A 37% Discount On Cash FlowYahoo · 8/18/2026
- DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued?Yahoo · 8/17/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
96.4K
- Sadie Stern · August 27, 2026 · Sale2.6K @ $88.37
- Jacob Steven Leach · August 22, 2026 · Tax Withholding1.5K @ $92.34
- Jereme M. Sylvain · August 22, 2026 · Tax Withholding1.5K @ $92.34
- Michael Jon Brown · August 22, 2026 · Tax Withholding1.5K @ $92.34
- Sadie Stern · August 22, 2026 · Tax Withholding1.5K @ $92.34
- Kevin R. Sayer · August 20, 2026 · Sale97 @ $91.41
- Kevin R. Sayer · August 20, 2026 · Sale7.4K @ $90.78
- Kevin R. Sayer · August 20, 2026 · Sale19.3K @ $89.71
- Bridgette P. Heller · August 12, 2026 · Sale1.0K @ $88.29
- Nicholas Augustinos · August 12, 2026 · Gift1.1K
- Mark G. Foletta · August 3, 2026 · Sale2.0K @ $85.32
- Mark G. Foletta · July 31, 2026 · Sale2.0K @ $80
- Kevin R. Sayer · July 20, 2026 · Sale26.8K @ $76.32
- Michael Jon Brown · July 15, 2026 · Sale1.7K @ $74.42
- Kevin R. Sayer · July 6, 2026 · Sale26.8K @ $72
Institutional Ownership
March 31, 2026
- Total shares held
- 341.07M
- Total value held
- $20.75B
- Institutional holders
- 947
Top holders this quarter
- Unknown38.96M
- Unknown25.02M
- Unknown17.93M
- Unknown15.60M
- Unknown12.92M
- Unknown12.35M
- Unknown9.75M
- Unknown9.33M
- Unknown6.33M
- Unknown5.59M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 29, 2026
FDA clears Abbott wearable, spotlight on glucose-tracking competition. The FDA approved Abbott's first wearable device that measures both ketones and glucose at the same time, a development that puts fresh attention on the glucose-monitoring space where DexCom operates. The approval gives patients a new option, adding to competitive pressure on existing continuous glucose monitor makers. Separately, a third-party analysis highlighted DexCom as a reasonably valued growth name with strong momentum, while another piece covered peer Embecta's turnaround prospects in diabetes care products. Together, these items frame DexCom within a competitive and fast-evolving diabetes technology market.